Saúde Pública/Medicina Humanitária

EMA recomenda a aprovação da vacina da Pfizer-BioNTech para crianças de 5 a 11 anos.

26 Nov, 2021 | 12:06h

Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 – European Medicines Agency

Conteúdos relacionados:

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

What COVID vaccines for young kids could mean for the pandemic.

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.

FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

Comentário no Twitter

‼️ EMA recommends approval of BioNTech/Pfizer’s #COVID19vaccine, Comirnaty, for children aged 5 to 11.

In this population, the dose of #Comirnaty will be lower than that used in people aged 12 and above.

Read the full press release: https://t.co/uqqBAklVvl pic.twitter.com/NZQhli4SDl

— EU Medicines Agency (@EMA_News) November 25, 2021

Variante fortemente mutada do coronavírus põe os cientistas em alerta – “Pesquisadores estão correndo para determinar se uma variante de alta transmissibilidade na África do Sul é uma ameaça à efetividade das vacinas contra COVID.”

26 Nov, 2021 | 12:03h

Heavily mutated coronavirus variant puts scientists on alert – Nature

Ver também:

Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern – BBC

WHO calls special meeting to discuss new Covid variant found in South Africa with ‘a large number of mutations’ – CNBC

New COVID-19 Variant With Multiple Concerning Mutations Identified in Southern Africa – Health Policy Watch

Scientists warn of new Covid variant with high number of mutations – The Guardian

South Africa detects new COVID variant with many mutations – MedicalXpress

Comentário relacionado no Twitter (fio – clique para saber mais)

THREAD on the new variant B.1.1.529 summarising what is known from the excellent South African Ministry of Health meeting earlier today

TLDR: So much uncertain but what *is* known is extremely worrying & (in my opinion) we should revise red list immediately.

This is why: 1/16

— Prof. Christina Pagel (@chrischirp) November 25, 2021

Editorial | Vacine-se o mundo.

26 Nov, 2021 | 12:01h

Vax the world – Science

Comentário do autor no Twitter

VAX THE WORLD!

is our wish/plea on #Thanksgiving day

Read our editorial in @ScienceMagazine by @yodifiji and me

Grateful to Lisa Chong, @hholdenthorp & @MeaganPhelan https://t.co/NiwMiEyCld pic.twitter.com/xbj0RF4lQe

— Madhu Pai, MD, PhD (@paimadhu) November 25, 2021

M-A | Comparação da eficácia clínica das vacinas contra COVID-19.

26 Nov, 2021 | 11:59h

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis – Scientific Reports

[Preprint] Respostas sorológicas ao reforço de vacina contra COVID-19 na Inglaterra.

26 Nov, 2021 | 11:56h

Serological responses to COVID-19 booster vaccine in England – medRxiv

Comentário do autor no Twitter (fio – clique para saber mais)

1/ Our preprint on #SARSCoV2 antibody responses in UK adults receiving a #COVID19 vaccine booster with the Pfizer vaccine at least 6 months after primary immunisation with Pfizer or AZ vaccine, which was given at an extended interval (8-12 wks) … 🧵

👉 https://t.co/JYxwH4JM51

— Shamez Ladhani (@ShamezLadhani) November 25, 2021

Diretriz provisória da OMS sobre a vacinação de crianças e adolescentes contra a COVID-19.

25 Nov, 2021 | 15:20h

Interim statement on COVID-19 vaccination for children and adolescents – World Health Organization

Estudo de coorte baseado na população do Catar mostrou que as reinfecções tiveram 90% menos chances de resultar em internação ou morte do que as infecções primárias.

25 Nov, 2021 | 15:18h

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections – New England Journal of Medicine

Conteúdo relacionado: [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

Reinfecção por COVID-19: o papel da imunidade natural, das vacinas e das variantes.

25 Nov, 2021 | 15:17h

COVID-19 reinfection: the role of natural immunity, vaccines, and variants – Journal of Community Hospital Internal Medicine Perspectives

Conteúdo relacionado: [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

Perspectiva | Fabricantes de vacinas contra COVID-19 se planejam para os reforços anuais, mas não está claro se isso será necessário.

25 Nov, 2021 | 15:15h

COVID-19 Vaccine Makers Plan for Annual Boosters, but It’s Not Clear They’ll Be Needed – JAMA

As vacinas protegem contra a “long COVID”? O que dizem os dados – “Vacinas reduzem o risco de desenvolvimento de COVID-19 – mas os estudos discordam quanto à proteção contra ‘long COVID’”.

25 Nov, 2021 | 15:14h

Do vaccines protect against long COVID? What the data say – Nature

Conteúdos relacionados:

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)